At a glance
ClinicalIndex Comparison RecordN/ACompleted· 110 enrolled
Drug / intervention
Tranexamic Acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigation of the Blood Sparing Properties of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty
In Brief
A clinical study evaluating Tranexamic Acid and Placebo for Blood Loss and 4 related conditions. Completed, enrolled 110 participants across 1 site.
Detailed Summary
To compare intravenous Tranexamic Acid (TXA) versus normal saline placebo to determine whether or not TXA administration reduces blood loss, decrease in hemoglobin, and rate of transfusions following anatomic and reverse total shoulder arthroplasty (TSA) surgeries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Loss, Anatomic Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Transfusion, Tranexamic Acid
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedOct 2015
Primary CompletionApr 2017
TodayJul 2026
First PostedOct 7, 2015
Enrollment StartSep 1, 2015
Primary CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.7 years ago
Interventions
Tranexamic Aciddrug
Placebodrug